LATEST ALERTS
Regulatory developments from the US, EU, Germany, Italy, India, Israel and Myanmar – and news of an “illegal” incursion into Austria by undercover Swiss border guards
The chief medical officer of the US National Football League (NFL) remains wary of letting players use CBD, despite a number of stars coming forward to endorse it
In our look at the regulatory picture in India we find that while CBD is regulated at a federal level, states also have their own rules and regulations with some more lenient than others
South Dakota governor Kristi Noem has explained why she continues to oppose hemp legalisation in the state; Flanders in Belgium is seeing enforcement action against CBD shops because of CBD oils and teas; Australian state Victoria may yet see hemp farming legalised as attitudes appear to be softening; and much more…
The launch of many CBD-containing foods, beverages and cosmetics in California has been delayed further as a bill legalising their sale is now not expected to pass before the end of the legislative session, which ends on on 13th September
Americans for Safe Access has issued the Patient’s Guide to CBD, Ireland sees increase in hemping-growing licence applications, and over 6000 plants have been seized in Portugal
Austrian and German police policy, local THC decision in Italy, Slovakian de-scheduling, Croatian proposals, US federal and state rulings and Israeli priorities come under the regulatory spotlight
Consumers looking for the medical benefits of cannabis are willing to pay a premium for high-CBD flowers, according to the findings of a new study by a group of US universities
CBD supplier Kannaway says it has been granted licences confirming compliance with the law and permitting free sale of a product in an EU member state – Bulgaria – as well as in Russia
The precise role Mexico’s government should play in a future cannabis industry was among the major issues discussed at a recent three-day event hosted by the country’s Senate
CBD-Intel’s regular round-up of regulatory news features items from the US, Mexico, Germany, Italy, Spain, Thailand, Trinidad and Tobago, and the self-governing UK dependency of Jersey
The panel responsible for recommending which drugs England’s National Health Service (NHS) should prescribe may recommend against the organisation using cannabis-based medical products.
The latest news and developments in the CBD industry worldwide rounded up in CBD-Intel’s weekly News In Brief.
CBD-Intel’s regular round-up of regulatory news features items from Portugal, the UK, Germany, Italy, Denmark, North America, Mexico, Colombia and Zimbabwe
CBD-Intel’s regular round-up of regulatory news features items from Germany, Italy, France, the Netherlands, Spain, Luxembourg, Canada, the US and South Africa
A European review committee has recommended that British company GW Pharmaceuticals’ Epidyolex (known as Epidiolex in the US) be licensed as a medicine in the European Union.
Many US senators seem ready to pass a law allowing financial institutions to work with CBD businesses. That’s if a hearing on the SAFE Banking Act is any indication
The US Food and Drug Administration (FDA)’s request for comments on regulating cannabis-related products drew 4492 responses covering a dizzying array of views
CBD-Intel brings you regulatory updates and snippets from the US, UK, Italy, Germany and Belgium
CBD-Intel’s regular round-up of regulatory snippets features news from the US, Europe and China
While the US FDA looks at paths for providing CBD research and routes to market, Congress may have a further opportunity to encourage legal developments in that direction
Attention in Washington is increasingly focused on CBD, with the US Congress striving to address regulation and the FDA promising policy action soon
CBD has turned Washington upside down, with a legal expert at the conservative Heritage Foundation testifying to Congress on behalf of federalism over states’ rights and free enterprise
CBD-Intel brings you regulatory updates from Italy, France, Turkey, New Zealand, El Salvador, the US states of Delaware and South Dakota and the island territory of Guam
The UK Centre for Medical Cannabis (CMC) has called for a Cannabinoid Clinical Trials Authority to regulate and test cannabis-based medicinal products
An extra helping of regulatory news from CBD-Intel brings you snippets from Argentina, Turkey, Lithuania, Estonia, the US House of Representatives and the state of Iowa
A German CBD company claims it can’t sell 90% of its stock following action by local authorities, while others are said to be facing charges of involvement in the illegal drug trade
A group of British MPs is recommending that more trials and research are carried out into cannabis-based medical products (CBMPs), including those containing CBD
The Canadian government has taken a first step towards allowing health products containing CBD – and potentially other cannabinoids – without a prescription
Smaller CBD stakeholders should not fear the entrance of big business into the market, according to one expert who explains how larger firms can help ease the regulatory path
A round-up of the week’s relevant regulatory news in the global CBD market for CBD-Intel, with updates from around the US, Belgium, France, Latvia, and Colombia
As regulations in China continue to evolve, we look at developments in the third Chinese province to consider new regulations for industrialised hemp
A landmark decision by South Africa’s now former health minister Aaron Motsoledi has legalised lower dosage CBD. But there’s a catch – the ruling only applies until May 2020
The number of French CBD shops reopening after facing legal action continues to rise, with at least seven shopkeepers acquitted of charges against them
Canada is the centre for the world’s largest cannabis companies and has recently implemented a wide-ranging new regulatory environment for all cannabis products
British national newspapers have run nearly 300 articles related to CBD over the last year – and the lion’s share have been overwhelmingly positive
International cannabis company Tilray has denied an accusation by the British Paediatric Neurological Association that it failed to provide sample products for testing
A meeting between the US FDA and members of the CBD industry provided the agency with plenty of information, but threw little light on the path it is likely to take
As part of our ongoing series of concise reports on how CBD is regulated across the US, we look at Florida – where a new law is on the way
CBD continues to gain ground across sports in North America; with recent visibility in sports like rugby and baseball, and no general proscription against CBD use from the World Anti-Doping Code, it may be making headway into American football.
Catch up on the latest CBD business news with CBD-Intel’s weekly round-up of stories.
Banking associations from all across the US have written to the Senate to advocate for a hearing on cannabis banking reform
Catch up on the latest CBD business news with CBD-Intel’s weekly round-up of stories.
Many parties taking part in the current European parliamentary elections would like to see more research on the effects of CBD before passing pro-CBD legislation
The first in a new weekly round-up from around the world brings you news from India, Canada – and the International Space Station
The first in a new weekly round-up from around Europe brings you news from Belgium, Germany, Switzerland, the Netherlands, the Czech Republic, Lithuania and the EU
The Tennessee legislature has enacted a bill which defines “smoking hemp”
Funding is available for Irish CBD businesses from Enterprise Ireland, a government body facilitating business development
The Italian CBD market should not be severely curtailed despite deputy prime minister Matteo Salvini’s threat to destroy the legal cannabis industry
Elavon Inc, a subsidiary of US Bank that processes card transactions, will cancel payment services for CBD businesses this week, documents seen by CBD-Intel reveal
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.
"*" indicates required fields
Submit your access request to explore how it can streamlines access to critical cannabis insights
"*" indicates required fields
